On July 26, 2019 KBL Merger Corp. IV (NASDAQ: KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC) executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with 180 Life Sciences (formerly known as CannBioRx Life Sciences Corp.).


Pursuant to the agreement, the stockholders of 180 will receive, in the aggregate, a number of shares of KBLM based on a pre-money valuation of $175 million (with deductions for liabilities existing at the closing of the transaction in excess of $5 million divided by 10).

KBLM and 180 are finalising their final proposal to the SEC ahead of closing.

Read the press releases concerning the merger here